Abstract Purpose: Therapeutic strategies to enhance the efficacy of radioimmunotherapy have not been explored. Motexafin gadolinium is a novel anticancer agent that targets redox-dependent pathways and enhances sensitivity of tumor cells to ionizing radiation. Experimental Design: We did preclinical studies examining motexafin gadolinium combined with rituximab and/or radiation in lymphoma cells. We subsequently completed a phase I clinical trial combining escalating doses of motexafin gadolinium concurrently with standard [ 90 Y]ibritumomab tiuxetan for patients with relapsed/refractory nonHodgkin's lymphoma. Results: In HF1 lymphoma cells, motexafin gadolinium and rituximab resulted in synergistic cytotoxicity (combination index, 0.757) through a mitochondrial-mediated caspasedependent pathway, whereas cell death in Ramos and SUDHL4 cells was additive. Motexafin gadolinium/rituximab combined with radiation (1-3 Gy) resulted in additive apoptosis. Twenty-eight of 30 patients were evaluable on the phase I clinical trial. Median age was 65 years (47-87 years), and histologies were marginal-zone (n = 1), mantle-cell (n = 3), diffuse large cell (n = 6), and follicular lymphoma (n = 18). Of all patients, 86% were rituximab refractory. Therapy was well tolerated, and no dose-limiting toxicity was seen. Overall response rate was 57% [complete remission (CR), 43%], with median time-to-treatment failure of 10 months (1-48+ months) and median duration-of-response of 17 months. Of note, all responses were documented at 4 weeks. Furthermore, in rituximab-refractory follicular lymphoma (n = 14), overall response rate was 86% (CR, 64%), with a median time-to-treatment failure of 14 months (2-48+ months). 
Clinical trials using single-agent [ 90 Y]ibritumomab tiuxetan and [
131 I]tositumomab in relapsed and refractory nonHodgkin's lymphoma are associated with overall response rates of 60% to 80% [complete remission (CR) rates of 20% to 50%] and median time-to-treatment failure or progression-free survival of 6 to 10 months (1-7). Two studies using [
Y]ibritumomab tiuxetan and [
131 I]tositumomab in rituximab-refractory follicular lymphoma showed overall response rates of 62% and 74%, with associated CR rates of 15% and 25%, respectively, and with associated median time-to-treatment failure of 7 and 9 months, respectively (5, 7) . One potential approach to increase the efficacy of radioimmunotherapy is through the addition of concurrent non-cross-resistant therapy. No previous studies, however, have been reported combining concurrent therapy with radioimmunotherapy.
Motexafin gadolinium (Xcytrin, Pharmacyclics, Inc.), an expanded porphyrin containing the lanthanide cation gadolinium, is a novel anticancer agent that targets the redox-dependent machinery of tumor cells (8) (9) (10) (11) (12) . Motexafin gadolinium is redox active as it catalyzes the intracellular oxidation of critical protein thiols and intracellular reducing metabolites that are protective to the tumor cell; depletion of these reducing metabolites leads to increased levels of reactive oxygen species ( Fig. 1 ; refs. 8-11, 13, 14) . Tipping the cellular redox balance within tumor cells through pharmacologic manipulation in favor of increasing intracellular reactive oxygen species and/or depleting reducing metabolites leads to oxidative stress and resultant induction of apoptosis. Clinically, motexafin gadolinium had been studied initially in combination with whole-brain radiation therapy to sensitize or increase the activity of ionizing radiation for patients with brain metastases from solid tumors (14) (15) (16) (17) (18) (19) (20) .
Our previous preclinical studies examined the effects of motexafin gadolinium in multiple myeloma cells and showed dose-dependent apoptosis through redox-dependent pathways (8) . Because motexafin gadolinium was known to enhance the sensitivity of tumor cells to ionizing radiation (14, 18, 21) , we reasoned that motexafin gadolinium combined concurrently with the radioimmunoconjugate [ 90 Y]ibritumomab tiuxetan would be additive or synergistic and provide higher response rates in relapsed/refractory lymphoma. We report here preclinical studies in lymphoma cell lines combining motexafin gadolinium with rituximab and/or radiation therapy. We subsequently completed a phase I trial using increasing doses of motexafin gadolinium, which was combined concurrently with fixed-dose [ 90 Y]ibritumomab tiuxetan, for patients with relapsed or refractory non-Hodgkin's lymphoma.
Materials and Methods
Cell lines and experimental conditions. HF1, SUDHL4, and Ramos lymphoma cell lines were cultured in RPMI 1640 (Invitrogen) with 10% fetal bovine serum, L-glutamine, and penicillin/streptomycin. Cells were maintained at 37°C with 5% CO 2 . HF1, SUDHL4, and Ramos cells were treated with control vehicle solution (5% mannitol), increasing concentrations of motexafin gadolinium (30-100 μmol/L), and/or increasing concentrations of rituximab (20-200 ng/mL). Motexafin gadolinium was prepared as a 2 mmol/L (2.3 mg/mL) formulation in 5% aqueous mannitol. Cultures were irradiated using a 137 Cs irradiator (model 40 γ cell; J. L. Shepherd and Associates) at a dose rate of 0.725 Gy/min and allowed to incubate for 72 h. Cells were harvested and washed twice with a solution of 0.5% bovine serum albumin in PBS.
Cell viability and apoptosis studies. Cell numbers were determined using the Model Z2 Coulter counter (Beckman-Coulter), and live cells were counted. Apoptosis was examined using FACS Calibur instrument (Becton-Dickinson) after staining the cells with Annexin V-fluorescein isothiocyanate and propidium iodide (Biosource-Invitrogen). In brief, 1 × 10 6 cells were washed with PBS and then labeled with AnnexinV-FITC and propidium iodide in the binding buffer, according to the AnnexinV-FITC apoptosis detection kit instruction provided by the manufacturer. Fluorescent signals of FITC and propidium iodide were detected at FL1 and FL3 channels, respectively. Percent apoptosis was determined by positivity for Annexin V. Data are presented as mean of 3 independent experiments in triplicate ± SD. Measurement of mitochondrial membrane potential was measured by flow cytometry using JC-1 staining. Cells were washed with HBSS and incubated with 4 μg/mL JC-1 dye in HBSS for 15 min at 37°C in an incubator. Cells were washed with HBSS and immediately subjected to flow cytometric analysis. Caspase 3 activation was measured (EnzChek Caspase-3 Assay Kit 2, Molecular Probes), whereas Q-VD-OPh was used for pan-caspase inhibition (Calbiochem). For further examination of apoptosis, the cleavage of poly(ADP-ribose) polymerase (PARP) was detected with Western blots. For Western blotting, cells were lysed in triple-detergent lysis buffer. Equal amount of protein was run on SDS-PAGE (Bio-rad) and then transferred to PVDF membrane. Membrane was blotted with anti-PARP antibody (Cell Signaling) and image quantitated using an Odyssey IR Imaging System (LI-COR).
Clinical trial. This was a phase I clinical trial that enrolled 30 relapsed/refractory non-Hodgkin's lymphoma patients from October 2003 through October 2007. The protocol was approved by the Northwestern University Institutional Review Board. All patients had histologically confirmed relapsed or refractory B-cell non-Hodgkin's lymphoma (all B-cell lymphoma histologies were allowed except Burkitt lymphoma). All nodal and bone marrow slides were reviewed by a single hematopathologist (D. Variakojis). Patients had <25% bone marrow involvement with lymphoma and an Eastern Cooperative Oncology Group performance status of ≤3, absolute neutrophil count of ≥1,500 cells/mm 3 , hemoglobin of ≥8.0 g/dL, platelet count of ≥100,000 cells/mm 3 , serum creatinine and total bilirubin of ≤2 mg/dL
Translational Relevance
We have been interested in novel therapeutic agents that induce apoptosis through oxidative stress pathways. We showed before in lymphoma cells that motexafin gadolinium induced intracellular oxidative stress with resultant apoptosis. Because motexafin gadolinium had been shown to enhance ionizing radiation in solid tumor models, we hypothesized that resistant melanoma cells and motexafin gadolinium may enhance the efficacy of radioimmunotherapy in lymphoma. We examined motexafin gadolinium in vitro here combined with rituximab and/or radiation in lymphoma cell lines, documenting additive or synergistic apoptosis, which occurred through mitochondrial-mediated pathways. We subsequently completed a phase I/II clinical trial in relapsed/refractory non-Hodgkin's lymphoma using escalating doses of motexafin gadolinium combined with standard radioimmunotherapy. Before this study, motexafin gadolinium had only been used clinically before combined with whole-brain radiation therapy for solid-tumor brain metastases. The data presented here represent true bench-to-bedside clinical/translational research.
each, expected survival of 3 mo, and no antineoplastic therapy for 4 wk (6 wk if treated with nitrosourea and/or mitomycin). One patient with diffuse large B-cell lymphoma was removed from the study because of the development of acute renal failure due to a rapidly growing and obstructing perinephric mass that developed before (and precluded ]ibritumomab tiuxetan was not to be given if the predicted delivered dose of radiation to any nontumor organ (liver, lung, kidneys, spleen, or heart) was >20 Gy or if the dose to the bone marrow was >3 Gy; no patient met this criterion. Patients received eight total doses of motexafin gadolinium (once daily), days 1 to 4 and 8 to 11, as shown in Supplementary Fig. S1A . Doses for motexafin gadolinium were based on actual body weight. Prophylactic antiemetics were given 30 min before motexafin gadolinium (e.g., compazine 5 mg). Day 1 and 8 rituximab infusions were given 1 h following the motexafin gadolinium infusion. γ Camera imaging with dosimetry was done for all patients on days 1, 2, 4, and 7.
Patients were treated in the Northwestern University General Clinical Research Center and had daily history and physical examinations from day +1 through day +11 of treatment, then weekly for the first month, and monthly for 6 mo. Complete blood count with differential was Fig. 1 . Motexafin gadolinium mechanism of action and cell growth studies using motexafin gadolinium with rituximab in lymphoma cells. A, motexafin gadolinium is an aromatic macrocycle containing complexed gadolinium(III). In the presence of oxygen, motexafin gadolinium accepts electrons from cellular reducing metabolites and forms superoxide and other reactive oxygen species by redox cycling. Motexafin gadolinium further disrupts redox-dependent pathways by targeting oxidative stress-related proteins such as thioredoxin reductase. Motexafin gadolinium oxidizes these metabolites forming reactive oxygen species, which leads to apoptosis. Motexafin gadolinium-related apoptosis has been shown to occur through a caspase-dependent mechanism (mitochondrially mediated). B, shows cell growth by Coulter counter analysis in HF1 cells with motexafin gadolinium and rituximab alone and combined. Induction of apoptosis, as measured by AnnexinV/propidium iodide, was increased with combined motexafin gadolinium/rituximab versus either agent alone. Clinically relevant concentrations of motexafin gadolinium and rituximab resulted in synergistic cell death (40 μmol/L and 48 ng/mL, respectively, associated with a combination index of 0.855; 50 μmol/L and 60 ng/mL, respectively, with a combination index of 0.757).
done weekly for the first 3 mo, then monthly for 1 y. Serum chemistries were done every 3 days from day +1 through day +12, then monthly for 6 mo. Response was assessed by an international workshop nonHodgkin's lymphoma response criteria (23) . As a correlative analysis to study the timing of response, the initial restaging computerized tomograms were done 4 wk following [
90 Y]ibritumomab tiuxetan treatment. Subsequent computerized tomograms were completed every 3 mo following or sooner if clinically indicated.
Phase I design. An abbreviated dose escalation of motexafin gadolinium was planned with three dose cohorts: 2.5, 3.5, and 5.0 mg/kg as the phase I component of the trial. The standard dosing of motexafin gadolinium in previous clinical trials combined with whole-brain radiation therapy was 5 mg/kg/d given 2 to 5 h before each fraction (19, 20) . Because of the known myelosuppressive toxicity of radioimmunotherapy based on the amount of lymphoma marrow infiltration (24) , the initial cohort accrued only patients with ≤5% bone marrow involvement ( Supplementary Fig. S1B ). Patients with 6% to 24% involvement began enrollment only after patients with ≤5% marrow involvement completed dose level 1. Patients among these two cohorts followed separate modified Fibonacci phase I schemas. At least three patients were treated at each dose level. All three patients at a given dose level must have completed follow-up through day 90 without suffering dose-limiting toxicity before patients were enrolled at the next dose level.
All toxicities were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0. The occurrence of any of the following during treatment constituted dose-limiting toxicity: grade 3 or 4 nonhematologic toxicity (other than grade 3 nausea or vomiting), grade 4 vomiting despite maximal antiemetic support, or the hematologic parameters grade 4 neutropenia and thrombocytopenia, either lasting longer than 14 d (measured in days from the first date in grade 4 to last date in grade 4 after nadir; growth factor and transfusion independent, respectively). The rationale for the above hematologic parameters was that, despite the modest cytopenias seen with [ 90 Y] ibritumomab tiuxetan, the range of grade 3 or 4 thrombocytopenia and neutropenia has been wide (ranges for "days from baseline to nadir" of 28-63 and 22-78 d, respectively, and ranges for "nadir to recovery" of: 7-53 and 4-21 d, respectively; ref. 24) .
Statistical analysis. The preclinical synergy studies, with associated combination indices between motexafin gadolinium and rituximab was tested using the isobologram analysis based on the method of Chou and Talalay (25) using the Calcusyn (Biosoft) software program. The method is based on the equation: CI = (D)1/(Dx)1 + (D)2/(Dx)2, wherein (D)1 and (D)2 are concentrations of drugs 1 and 2 that have x effect when used in combination and (Dx)1 and (Dx)2 are the concentrations of drugs 1 and 2 that have the same x effect when used alone. As of April 2006, 14 patients with ≤5% bone marrow involvement had completed dose escalation without dose-limiting toxicity, whereas only one patient had accrued to the 6% to 24% cohort. Thus, an expansion (10 patients) of accrual at the motexafin gadolinium 5.0 mg/kg dose level was allowed for patients with ≤5% bone marrow involvement, whereas accrual continued to the 6% to 24% marrow group. For the expanded enrollment, a predicted "good" overall response rate of 60% and a "poor" overall response rate of 30% for all patients were used, and for follicular lymphoma patients, a good overall response rate of 75% and a poor overall response rate of 50% were used. Using this information and type 1 error probability of 0.1, we calculated >84% power to detect the difference for all patients and >74% power to detect the above difference for relapsed follicular lymphoma patients, using an exact one sample test for response rate (P).
Time-to-treatment failure was calculated from day 1 of treatment to treatment failure (relapse, secondary malignancy, or death from any cause). Overall survival was calculated from day 1 of treatment to the date of death from any cause or until the date of last known follow-up. Duration of response was estimated from the day of response assessment until relapse, progression, or death from any cause. Survival analyses were done using Kaplan-Meier curves (26) . Prognostic factors were evaluated in univariate analyses using Cox proportional hazards regression (27) 
Results
Preclinical data. We and others (28) (29) (30) previously reported single-agent cytotoxicity with motexafin gadolinium in B-cell lymphoma cell lines (Raji, SUDHL-4, and HF1). We examined here the cytotoxicity of motexafin gadolinium with and without rituximab in the lymphoma cell lines, HF1, SUDHL4, and Ramos. In the follicular lymphoma cell line, HF1, modest in vitro concentrations of motexafin gadolinium and rituximab resulted in additive apoptosis (30 μmol/L and 36 ng/mL, respectively, with a combination index of 1.013), whereas increasing concentrations resulted in synergistic cell death (40 μmol/L and 48 ng/mL, respectively, associated with a combination index of 0.855; 50 μmol/L and 60 ng/mL, respectively, with a combination index of 0.757; Fig. 1B) .
Using similar concentrations, we found further evidence of apoptosis with higher levels of cleaved PARP ( Fig. 2A) and >50% loss of mitochondrial membrane potential ( Fig. 2B ) with combined motexafin gadolinium and rituximab (versus either agent alone). Apoptosis studies were also completed in SUDHL4 and Ramos lymphoma cell lines wherein additive cell death was seen (data not shown). In HF1 cells, caspase-3 activity was increased with motexafin gadolinium and, to a lesser extent, rituximab alone, whereas both agents combined resulted in additive increased caspase-3. Furthermore, the pancaspase inhibitor Q-VD-OPh resulted in substantial blockage of motexafin gadolinium and/or rituximab-induced apoptosis, including abrogation of caspase-3 activation (Fig. 2C and D) . We also studied cell death combining motexafin gadolinium and/or radiation (with and without rituximab) in HF1 cells (Fig. 2E) . When motexafin gadolinium was combined with rituximab or radiation (1-3Gy), an additive decrease in cell proliferation and induction of apoptosis were seen. The highest level of cell death was seen when motexafin gadolinium, radiation, and rituximab were combined.
Clinical trial patient characteristics. As shown in Table 1 , 19 of 29 patients treated on trial had indolent lymphoma (18 follicular lymphoma). The remaining 10 patients had aggressive histologies. The median age for all patients was 64 years, whereas one third were >75 years. Most patients had advanced stage disease at study entry, whereas 55% had bulky disease ≥5 cm. Median number of previous regimens was 2 (range, 1-4). Of note, 86% of all patients entered on this clinical trial had rituximab-refractory disease, defined as previous treatment with rituximab with no response or time-to-treatment failure of <6 months. Seventy-eight percent (14 of 18) of follicular lymphoma patients had rituximabrefractory disease.
Among the group of rituximab-refractory follicular lymphoma, median age was 60 years (range, 47-85 years), median of previous regimens was 3 (range, 1-4), 79% had stage III/IV disease, 55% had bulky disease ≥5 cm, and 72% had intermediate or high Follicular Lymphoma International Prognostic Index (FLIPI) (≥3) at study entry. Twelve of 14 of these patients had received previous alkylator-based chemotherapy, the most common regimen being R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone; 9 of 12). Among the 10 evaluable patients with relapsed/refractory aggressive lymphoma, median age was 77 years, and 70% were stage III/IV at study entry. Ninety percent of these patients had received frontline R-CHOP-like (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; anthracycline based) chemotherapy, whereas 90% of patients at time of study entry were rituximab refractory. Motexafin gadolinium combined with rituximab and/or radiation induced apoptosis. A, cleaved PARP was >4-fold increased in HF1 cells using motexafin gadolinium/rituximab combined versus either agent alone (motexafin gadolinium 40 μmol/L and rituximab 25 ng/mL). Cleaved PARP ratios are shown relative to Hsc70. B, we examined loss of mitochondrial membrane potential, which significantly decreased with combined motexafin gadolinium/ rituximab versus either agent alone (P < 0.001). C and D, the activation of caspase-3 and apoptosis (AnnexinV/propidium iodide) were measured in HF1 cells with motexafin gadolinium and/or rituximab in the presence of absence of the pan-caspase inhibitor Q-VD-OPh. Overall apoptosis and caspase-3 activity induced by motexafin gadolinium and/or rituximab was caspase dependent. E, shows motexafin gadolinium combined with ionizing radiation (with/without rituximab) in HF1 cells using motexafin gadolinium 40 μmol/L, rituximab 25 ng/mL, and radiation 1 and 3 Gy. Motexafin gadolinium combined with radiation showed additive apoptosis, whereas the addition of rituximab led to further additive cell death. FasL, Fas ligand; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; CI, combination index; XRT, radiation; rit, rituximab.
≤5% marrow involvement. Thus, motexafin gadolinium dose escalation for the group of patients with >5% bone marrow involvement was not completed. No dose-limiting toxicities were seen for the 14 phase I patients with ≤5% bone marrow involvement or the four phase I patients with >5% marrow involvement. The remaining patients (n = 11) received motexafin gadolinium at 5 mg/kg.
Efficacy. Twenty-eight patients were evaluable for response. The nonevaluable patient was a 75-year-old man with relapsed/refractory diffuse large B-cell lymphoma who died 3 months following motexafin gadolinium/[ 90 Y]ibritumomab tiuxetan therapy from accidental causes (before 3-month restaging studies; stable disease at 1 month). The overall response rate for all evaluable patients was 57% (16 of 28) ; most responses were complete (CR, 43%). Overall response rate by intent-to-treat for all patients (n = 30) was 53% (16 of 30), with 40% CR (12 of 30) . The efficacy data in the subgroup of patients with rituximab-refractory follicular lymphoma (n = 14) showed an overall response rate of 86%, with a CR rate of 64%.
Among the 10 evaluable patients with relapsed/refractory aggressive lymphomas, the overall response rate was 20%. The two responses, however, were both CRs in rituximab-refractory diffuse large B-cell lymphoma patients (overall response rate in diffuse large B-cell lymphoma, 29%). One of the related CRs lasted 11 months, whereas the other CR is ongoing (25+ months). Both of these patients were elderly (72 and 87 years of age) with rituximab refractory-transformed diffuse large B-cell lymphoma with no response to their previous chemotherapeutic regimen.
Of note, all responses in this trial were documented at 4 weeks following combined motexafin gadolinium/[
90 Y]ibritumomab tiuxetan therapy. Six patients with partial remissions at 4 weeks improved to CR at subsequent (3 month) restaging. However, no "new" responders were identified after 4 weeks. Besides histology (i.e., indolent lymphoma versus aggressive; P < 0.01), there were no predictive factors of response on univariate analysis (e.g., bulk disease, age, performance status, lactate dehydrogenase, or rituximab-refractory versus rituximabsensitive status).
At a median follow-up of 35 months, the median time to treatment progression (TTP) for all patients on intent-to-treat analysis (n = 30) was 10 months (range, 1-51+ months), and the median overall survival was not reached with 3-year overall survival of 77% (Fig. 3A and B) . The median duration of response for all patients was 17 months (range, 2-51+ months). With a median follow-up of 37 months, the median TTP for patients with rituximab-refractory follicular lymphoma was 14 months (range, 2-51 months), and the median overall survival was not reached with 3-year overall survival of 80% ( Fig. 3C and D) . The median duration of response for this group was 18 months (range, 4-51+ months). Safety. Therapy was well tolerated. Most toxicity was hematologic, whereas the percentage of grade 3/4 hematologic adverse events and the median time-to-hematologic nadir levels seemed similar to single-agent [
90 Y]ibritumomab tiuxetan (Table 3) . Grade 3/4 nonhematologic adverse events were uncommon (Table 3) . Two grade 3 nonhematologic toxicities were seen (one infection and one hypokalemia). At a median follow-up of 35 months, no secondary MDS or leukemia has been seen. The most common nonhematologic adverse event was a temporary olive-green discoloration of the skin (80% of patients). The skin discoloration was due to the dark-green color of motexafin gadolinium. The discoloration developed gradually after repeated dosing of motexafin gadolinium and completely cleared within 4 to 5 days after the last dose. Some patients developed a transient pruritic rash on their fingertips (n = 5) that also disappeared 3 to 4 days after completion of motexafin gadolinium. Other adverse events seen, as shown in Table 3 , included electrolyte abnormalities, liver enzyme abnormalities, and gastrointestinal symptoms, although most symptoms were mild and self-limiting.
Discussion
One strategy to increase the effectiveness of radioimmunotherapy is through combination with non-cross-resistant agents that may be additive or synergistic. Because of the activity of motexafin gadolinium combined with ionizing radiation in solid-tumor studies (16, 19, 20) , the absence of hematologic 7 wk (4-13) 11.8 (7.4-13.5) 18% 0%
Nonhematologic toxicity of motexafin gadolinium, our previous preclinical studies in hematologic malignancies (8, 28, 29) , and the current preclinical studies in lymphoma, we reasoned that motexafin gadolinium might enhance the antitumor activity of [ 90 Y]ibritumomab tiuxetan. To our knowledge, this report represents one of the first clinical trials combining a novel therapeutic agent concurrently with radioimmunotherapy for the treatment of lymphoma. We and others (8, 28, (30) (31) (32) (33) (34) (35) have shown that the production of oxidative stress through novel nonchemotherapeutic agents results in cell death in hematologic cancer cell lines. Motexafin gadolinium, also known as gadolinium texaphyrin, is a metalloporphyrin that had been developed as a radiation-and chemotherapy-enhancing agent (11, 14, 18) . Motexafin gadolinium is known to have selective tumor biolocalization, similar to naturally occurring porphyrins (12, 14, 36) . Animal studies using magnetic resonance scanning and radiolabeled drug documented rapid clearance of motexafin gadolinium from blood and normal tissues with delayed clearance from tumors (21, 37) . Since this clinical study was initiated, motexafin gadolinium alone was shown to induce apoptosis in lymphoma cell lines (28) (29) (30) . Chen et al. (29) showed that motexafin gadolinium triggered the mitochondrial apoptotic pathway and activated the caspase system in non-Hodgkin's lymphoma cells. In SUDHL4, Ramos, Raji, and HF1 cells, motexafin gadolinium was shown to induce oxidative stress as shown by oxidation of 2′,7′-dichlorofluorescin-diacetate to 2′,7′-dichlorofluorescein, whereas gene expression studies showed increased metal response element-binding transcription factor 1-regulated and hypoxia-inducible transcription factor 1-regulated genes (28) . These genes were likely activated as an adaptive response to motexafin gadolinium-induced apoptosis. Ramos et al. (30) Fig. 3 . Intent-to-treat progression-free survival and overall survival Kaplan-Meier curves for all patients (n = 30) and for rituximab-refractory follicular lymphoma patients (n = 14). A and B, the progression-free survival and overall survival for all patients enrolled on trial. At a median follow-up of 35 mo, the median progression-free survival was 10 mo and the median overall survival was not reached (progression-free survival and time-to-treatment failure were identical). C, the median progression-free survival for rituximab-refractory follicular lymphoma of 14 mo. This compares with data by Witzig et al. reported that motexafin gadolinium increased Akt phosphorylation, while specific inhibitors of Akt were synergistic combined with motexafin gadolinium. We found in the current preclinical studies that motexafin gadolinium combined with rituximab led to synergistic apoptosis and that cell death seemed to occur through a mitochondrial-related pathway that was caspase dependent. Furthermore, motexafin gadolinium combined with radiation resulted in an increase in apoptosis that was additive.
Dosing of motexafin gadolinium in this study was conservative. When this trial was opened in 2003, motexafin gadolinium had only been used clinically before as a radiationsensitizing agent in combination with whole-brain radiation therapy for the treatment of patients with metastatic brain disease. The maximum tolerated dose as determined by previous solid-tumor phase Ib/II studies with motexafin gadolinium (given daily for 10 days) with concurrent whole-brain radiation therapy was 6.3 mg/kg (17) . Furthermore, plasma pharmacokinetics has shown no relationship between maximum concentration (Cmax) or area under the curve and motexafin gadolinium dose. In the phase III metastatic brain clinical trials, patients received 10 consecutive daily doses of motexafin gadolinium at 5 mg/kg/d (16, 19 (24) . Continued treatment with motexafin gadolinium, beyond the 8 doses given here, was not done in part because the antilymphoma activity of motexafin gadolinium was not appreciated at the time this trial was planned.
The efficacy data from the phase I/II trial here using combined motexafin gadolinium/[ 90 Y]ibritumomab tiuxetan compare favorably to previous single-agent radioimmunotherapy reports. In particular, there was a strong signal of clinical activity in the current clinical trial in the subset of rituximabrefractory follicular lymphoma. Witzig et al. (5) , using [ 90 Y]ibritumomab tiuxetan, reported an overall response rate of 74%, with associated 15% CR rate and median TTP of 6.8 months. In a similar patient population here, motexafin gadolinium/ [ 90 Y]ibritumomab tiuxetan was associated with a marked increase in CR rate (64%) and approximate doubling of time-to-treatment failure (14 months). In diffuse large B-cell lymphoma, the overall response rate here was 29% (CR, 29%), both responses in transformed diffuse large B-cell lymphoma. Morschhauser et al. (38) showed in relapsed/refractory diffuse large B-cell lymphoma (nontransformed) that the overall response rate in patients who received previous rituximabbased chemotherapy was 19% (CR, 8%).
The time-to-response with radioimmunotherapy has never been examined. One notion has been that the time-toresponse may be delayed, in part given the delayed myelosuppression associated with radioimmunotherapy. We found in 90 Y]ibritumomab tiuxetan alone would be needed. Given the apparent single-agent cytotoxic activity of motexafin gadolinium in lymphoma seen in preclinical data, it would be rational in future trials to apply "extended dosing" of motexafin gadolinium.
Delayed thrombocytopenia and neutropenia have been the most common hematologic side effects documented with [ 90 Y]ibritumomab tiuxetan therapy, with median days from baseline to nadir of 43 and 50 days, respectively (5, 39, 40) . The hematologic toxicity seen in this trial (Table 3) seemed similar to previous single-agent [ 90 Y]ibritumomab tiuxetan (median nadir counts with 0.4 mCi/kg): 50,000/mm 3 for platelets, 1,100/mm 3 for neutrophil count, and 9.9 g/dL for hemoglobin (24, 40) . The most common nonhematologic adverse event seen with motexafin gadolinium was a temporary greenish discoloration of the skin, as described before. This has been seen in all previous motexafin gadolinium clinical trials that used >3 to 4 consecutive daily doses (16, 17, 36, 37) , although the symptoms (including pruritis) are mostly mild and self-limited. Other nonhematologic adverse events seen here included several electrolyte changes, liver enzyme abnormalities, and gastrointestinal symptoms, although most symptoms were mild (grade 1) and transient. It should be noted that patients were followed very closely in this clinical trial, including daily history and physical examinations (during motexafin gadolinium dosing), whereas serum chemistry and hepatic function testing was done every 2 to 3 days initially. Other adverse events in the current trial did not seem to have increased compared with previous radioimmunotherapy studies.
In conclusion, novel therapeutic agents exist, such as motexafin gadolinium, which may be safely combined with radioimmunotherapy. We found that motexafin gadolinium, when given together with [ 90 Y]ibritumomab tiuxetan, did not seem to increase hematologic or other toxicity. Furthermore, all responses here occurred promptly (within 4 weeks), although a high rate of CRs was seen, especially in rituximab-refractory follicular lymphoma patients. Continued preclinical and clinical studies combining other novel therapeutic agents, such as bortezomib (41) and CpG 7909 (42), together with radioimmunotherapy are warranted.
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